Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

International Journal of Clinical Practice

Volumn 58, Issue 9, 2004, Pages 833-837

  Belcher, Glyn ^a   Lambert, C ^a   Goh, K L ^a   Edwards, G ^a   Valbuena, M ^a  

^a Takeda Europe R and D Centre   (United Kingdom)

Author keywords

Cardiovascular outcome; Gliclazide; Metformin; Pioglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLICLAZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ADULT; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT DISORDER; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EDEMA; FEMALE; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; WEIGHT GAIN;

BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; GLICLAZIDE; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; THIAZOLIDINEDIONES;

EID: 7744238962     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00291.x     Document Type: Article

References (11)

1. Sowers JR. Update on the cardiometabolic syndrome. Clin Cornerstone 2001; 4: 17-23.
2. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 2002; 16: 401-15.
3. Van Wijk JP, De Koning EJ, Martens EP et al. Thiazolidine-diones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-9.
4. Dandona P. Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions. Diabetes Technol Ther 2002; 4: 809-15.
5. Hanefeld M, Belcher G. Safety profile of pioglitazone. Int J Clin Pract Suppl 2001; 121: 27-31.
6. Kotchen TA, Zhang HY, Reddy S et al. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 1996; 270 (3 Part 2): R660-6.
7. Verma S, Bhanot S, Arikawa E et al. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 1998; 56: 7-16.
8. Fullert S, Schneider F, Haak E et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-6.
9. Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003; 23: 861-5.
10. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333-43.
11. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-63.